-
New gene therapy successfully restores part of the visual function of blind people for the first time
Time of Update: 2021-06-03
Today, the authoritative academic journal "Nature-Medical" published an exciting clinical trial result: a blind patient was diagnosed with retinitis pigmentosa 40 years ago.
[2] With engineered proteins, scientists use optogenetics for the first time to help a blind patient see again.
-
Type 1 diabetes antibody drug teplizumab won the U.S. FDA advisory board...
Time of Update: 2021-06-03
In clinical trials supporting the drug NDA, a 2-week course of teplizumab treatment can delay the onset of type 1 diabetes by an average of 2 years.
-
Roche CEO joins in opposing the abandonment of COVID vaccine patent...
Time of Update: 2021-05-23
Earlier this month, the Biden government unexpectedly took an action to support a proposal made by the World Trade Organization (WTO) that would temporarily suspend patent rights for COVID-19 products.
-
8 Regional Consumables Alliance Procurement Results Announced
Time of Update: 2021-05-23
We have seen that in the centralized procurement of the eight cities of Xinxiang Medical Consumables Alliance, a total of 18 companies for homocysteine testing reagents have been selected, among which Top Nine Biology, Mike Biology, and Shenzhen Mindray are among the market leaders.
-
Two Science Sub-Journals: Smart Cell Therapy for the Treatment of Solid Tumors Released
Time of Update: 2021-05-23
They found that it uses a two-step method to hunt down cancer cells, which can completely eliminate human patient-derived tumors in mouse brains, without dangerous side effects, and without the current high risk of recurrence associated with immunotherapy for solid tumors.
-
FDA suspends early trials of rare heart disease gene therapy RP-A501
Time of Update: 2021-05-23
An important factor driving its recent surge in market value is that early clinical data supports the potential of its gene therapy RP-A501 to treat Danon Disease.
-
Roche's oncology business continued to be impacted by biosimilars in the first quarter, and total sales fell by 19...
Time of Update: 2021-05-10
Avastin's sales during the quarter fell sharply by 42% to 863 million Swiss francs.
Roche recently released the results of a first-in-class positive study showing that Tecentriq can prevent postoperative recurrence or death in patients with early-stage non-small cell lung cancer.
-
Mindray's 2020 financial report: revenue of 21.026 billion and net profit increased by 42%. Research...
Time of Update: 2021-05-10
026 billion yuan, a year-on-year increase of 27%; the net profit attributable to shareholders of listed companies in 2020 is approximately 6.
Mindray Medical was listed on the New York Stock Exchange in 2006 and returned to China from privatization in 2016, with a market value of 23 billion yuan ($3.
-
Nat Commun: CRISPR technology reveals the mechanism of cancer spread
Time of Update: 2021-05-03
Information source: CRISPR study identifies gene that plays key role in metastasis of cancers to the lungs
Information source: CRISPR study identifies gene that plays key role in metastasis of cancers to the lungs
-
Pratt & Whitney Insurance: Is it on the eve of the outbreak of commercial health insurance that swept 50 million people?
Time of Update: 2021-05-03
In the past few months, with the low price of less than 100 yuan and the promised high insurance coverage-over one million, a new type of commercial health insurance-inclusive insurance has swept nearly 40 cities, and the number of people insured It broke 10 million quickly.
-
Cell Host Microbe: Pfizer vaccine protects South African strains...
Time of Update: 2021-05-03
According to a recent study, researchers from Ben Gurion University of the Negev (BGU) found that the Pfizer coronavirus vaccine is less effective against the South African variant, compared to the British variant and the original SARS-CoV- The neutralization ability of the two strains remained at a high level.
-
PNAS analysis: Develop a new type of cancer immunity that can target common genetic mutations...
Time of Update: 2021-05-03
Recently, in a research report titled "Targeting loss of heterozygosity for cancer-specific immunotherapy" published in the international journal PNAS, scientists from Johns Hopkins University School
-
Boehringer Ingelheim's new drug BI 425809 for schizophrenia received clinical approval
Time of Update: 2021-05-03
The analysis results of MCP-Mod (a dose assessment model) showed that 5 of the 6 dose-response models showed significant differences in overall composite T scores of MCCB from baseline; compared with placebo, the MCCB of the BI 425809 10 mg and 25 mg dose groups The overall composite T score changed the most from baseline (adjusted average difference: 10 mg: 1.
-
Roche discontinues Phase III clinical study of antisense RNA therapy tominersen
Time of Update: 2021-05-03
Roche said that after the independent data committee "recommended the potential benefits and risk status of study participants based on investigating therapies," the company has stopped the administration of the third phase clinical study of the antisense drug tominersen for huntingtin and mutants.
-
195.8 billion!
Time of Update: 2021-05-02
is studying a possible valuation of this large medical supplies company, the transaction price may be as high as 30 billion US dollars, equivalent to about 195.
According to Reuters information on April 11, the Italian diagnostic group DiaSorin SpA stated that it will acquire the US-based Luminex company for $1.
-
Overview of structural biology technology｜MicroED, cryo-electron microscope SPA and X-ray...
Time of Update: 2021-05-02
In recent years, with the advent of direct detection device (DDD) and the development of various data processing software, cryo-electron microscope analysis of the three-dimensional structure of biological macromolecules accounted for an increasing proportion (see Figure 1) .
-
110 pharmaceutical companies posted their first quarter transcripts!
Time of Update: 2021-05-02
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
-
The TCM Psychology and Sleep Disorder Treatment Seminar was held as scheduled for the TCM Department of Mingde Hospital...
Time of Update: 2021-05-02
Ma Li, director of the Department of Traditional Chinese Medicine of Beijing Mingde Hospital, said that under the huge pressure of today's society, the emotional problems and sleep disorders of urban white-collar workers have become one of the main contradictions in the topic of national health in first-tier cities.
-
Annual report of 217 A-share pharmaceutical companies: Fosun Pharma's R&D of 4 billion tops the list
Time of Update: 2021-05-02
According to statistics from E-pharmaceutical managers, as of April 14, 2021, a total of 217 A-share listed biomedical companies have issued annual reports.
In 2019, Zixin Pharmaceutical's revenue and net profit attributable to shareholders of listed companies decreased by 35.
-
Kangmei Pharmaceuticals exploded again!
Time of Update: 2021-05-02
Kangmei Pharmaceutical was listed on the Shanghai Stock Exchange in 2001, with a listed market value of less than 900 million.
